SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 is experiencing heightened volatility and a sharp reversal following a televised address by President Trump, which signaled a prolonged military operation in Iran and dashed investor hopes for an immediate ceasefire. Community discussion is dominated by concerns over escalating energy costs, frustration with the administration's inconsistent messaging, and widespread skepticism regarding the market's stability heading into the upcoming long weekend.

Invesco QQQ Trust Series 1 - Units of beneficial interest

Invesco QQQ Trust (QQQ) is seeing intense trading activity as investors react to the potential for further military escalation in the Middle East following upcoming government remarks. The community is sharply divided, with traders debating whether market price action reflects a genuine de-escalation of conflict or a temporary bull trap driven by misinformation, leading many to adopt a defensive, cash-heavy stance ahead of the holiday weekend.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently caught in a volatile tug-of-war as investors react to high-stakes geopolitical developments in the Middle East and ongoing market manipulation concerns surrounding political rhetoric. While some bulls remain optimistic about institutional adoption and long-term scarcity, the community is actively debating whether current price action represents a genuine bottom or a trap ahead of further macro-driven downside.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and the online community closely monitor a highly anticipated prime-time address regarding the ongoing conflict in Iran. The stock is facing intense volatility and polarizing debate as the community actively discusses the potential market impact of the president's military strategy, geopolitical uncertainty, and broader skepticism surrounding the company's long-term operational viability.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently drawing intense community focus due to speculative volatility ahead of its upcoming Q1 delivery report, with discourse deeply polarized between bulls betting on a demand recovery and bears fixated on broader macroeconomic instability. Sentiment remains heavily influenced by geopolitical headlines and debates over leadership, as traders weigh the company's long-term AI-driven prospects against immediate delivery figures.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is seeing heavy volatility and intense debate as investors weigh the impact of potential Bitcoin price fluctuations, ongoing corporate share dilution, and market concerns over quantum computing threats to crypto security. The community is sharply divided, with some betting on a major short squeeze and rebound, while others characterize the stock as a precarious leverage play nearing a potential breakdown.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing heightened investor interest following a major deal to repurchase a significant stake in its Ireland Fab 34, a move interpreted as a strategic play to regain control over key manufacturing assets. The community is actively debating the company's long-term foundry turnaround potential against near-term geopolitical risks and broader market volatility.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is generating significant community buzz as holders highlight its identity as a permissionless brand that incentivizes real-world product development and active community participation. Supporters are pointing to the project's persistent growth and diverse initiatives as key reasons for their long-term conviction, frequently encouraging others to join the movement before it reaches broader market recognition.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is currently trending as investors react to the confirmed April launch window for the BlueBird 7 satellite aboard Blue Origins New Glenn, while the broader community remains locked in a fierce debate between bullish believers in the satellite broadband thesis and bearish skepticism over execution delays, dilution risks, and market volatility.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience Holdings is trending due to heightened retail interest in its low-float, meme-stock characteristics and potential for high volatility, with community members actively monitoring its history of rapid spikes alongside intense short-squeeze speculation. Discussions are heavily focused on the stock's tight share structure and historically high borrow fees, drawing comparisons to previous parabolic market runners.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AI and Biotech Enter a Stock Picker’s Market

The market is sending a mixed but telling signal: innovation is accelerating, but only the most disciplined and well-positioned companies are keeping pace. Across AI, biotech, and micro-cap tech, recent developments highlight a widening divide between firms gaining validation and those fighting to maintain footing in public markets. $BFRG, $TGNT, $LTRN, $VRAX, $KIDZ, $HKIT

Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost...

Why Is Lantern Pharma Stock Soaring Monday?

Lantern Pharma shares rebound in premarket trading as the company debunks a false report regarding CEO Panna Sharma's departure.read more...

<ul class="summary-bullets"><li>PMGC Holdings said Friday that its unit, NorthStrive Biosciences, amended a deal with MOA Life Plus to run human trials for EL-22 and EL-32, targeting muscle and lean mass preservation.</li><li>Iterum Therapeutics announced on Friday that it had filed a winding-up petition in Ireland, which is set to be heard on April 13, 2026.</li><li>Lantern Pharma said the FDA cleared its Investigational New Drug application for STAR-001, a targeted therapy for relapsed or refractory CNS cancers.</li></ul>U.S. equities were in the green in Monday’s pre-market trade amid the ongoing tensions in the Middle East, with President Donald Trump stating on Sunday that Iran had agreed to the 15-point ceasefire plan “for the most part.”At the time of writing, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which tracks the S&amp;P 500 index, was up 0.49%; the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust ETF</a> (QQQ) rose 0.42%; and the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA) gained 0.47%. Retail sentiment on Stocktwits regarding the S&amp;P 500 ETF was in the ‘extremely bearish’ territory.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Monday’s pre-market trade:</h2><a href="https://stocktwits.com/symbol/ELAB">PMGC Holdings Inc. (ELAB)</a>PMGC Holdings shares soared more than 66% in Monday’s pre-market session. The company announced on Friday that its wholly-owned subsidiary, NorthStrive Biosciences, has amended its existing agreement with MOA Life Plus for human clinical trials of its lead candidate EL-22, as well as EL-32, to study the preservation of muscle and lean mass.<a href="https://stocktwits.com/symbol/ELAB">ELAB stock</a> is down 95% year-to-date.<a href="https://stocktwits.com/symbol/ITRM">Iterum Therapeutics PLC (ITRM)</a>Iterum Therapeutics shares more than doubled to soar 110% in Monday’s pre-market trade. The company announced on Friday that it had filed a winding-up petition in Ireland, which is set to be heard on April 13, 2026.<a href="https://stocktwits.com/symbol/ITRM">ITRM stock</a> is down 90% year-to-date.<a href="https://stocktwits.com/symbol/LTRN">Lantern Pharma Inc. (LTRN)</a>Lantern Pharma shares gained more than 17% in Monday’s pre-market session. The company announced on Friday that its CEO Panna Sharma continues to serve the Dallas-based biopharmaceutical company. It also announced that the U.S. Food and Drug administration (FDA) cleared its Investigational New Drug (IND) application for STAR-001, its treatment for patients with relapsed or refractory central nervous system (CNS) malignancies.<a href="https://stocktwits.com/symbol/LTRN">LTRN stock</a> is down 63% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bur-stock-sinks-after-us-appeals-court-ruling-argentina-ypf-connection/cZ3HJ4aRIm7">BUR Stock Sinks 40% Following A Reported US Appeals Court Ruling — What Is The Argentina Connection?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Top Pre-Market Gainers Today — ELAB, ITRM, LTRN Among Stocks Soaring Before The Bell

U.S. equities gained in Monday’s pre-market trade after President Donald Trump stated that Iran had agreed to the 15-point proposal for the most part.

Equity

Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

Lantern Pharma Inc. (NASDAQ: LTRN) (Lantern or the Company), an AIdriven, clinicalstage oncology company leveraging its proprietary RADR platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on...

Lantern Pharma Stock Falls 10% After FDA Clears Investigational New Drug Application For STAR-001

(RTTNews) - Stock of Lantern Pharma Inc. (LTRN) is moving down about 10 percent on Friday morning trading after the company, along with its subsidiary Starlight Therapeutics, announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application...

AI, Biotech, and Biologics Drive Big Narratives

A new wave of healthcare innovation, powered by artificial intelligence, next-generation biologics, and shifting regulatory pathways, is colliding with market dynamics to create both breakthrough potential and high-volatility trading setups. $ARTL, $TGNT, $ADMA, $RCKT, $LTRN, $GCTK

<ul class="summary-bullets"><li>STAR-001 is a precision oncology compound discovered using Lantern’s proprietary RADR AI platform.</li><li>The study will evaluate the drug both as a standalone treatment and in combination with Spironolactone.</li><li>The trial to be conducted with the Pediatric Oncology Experimental Therapeutics Investigators' Consortium.</li></ul>Shares of Lantern Pharma Inc. (LTRN) surged nearly 18% in pre-market trading on Friday after the biotech firm said that the U.S. Food and Drug Administration cleared its Investigational New Drug (IND) application for STAR-001, allowing the company to begin a Phase 1 pediatric clinical trial for central nervous system cancers.STAR-001 is a precision oncology compound discovered using Lantern’s proprietary RADR AI platform, which helped identify its potential in CNS and pediatric CNS indications, the company said. The study will evaluate the drug both as a standalone treatment and in combination with Spironolactone in children with relapsed or refractory CNS cancers.The trial will be conducted in collaboration with the Pediatric Oncology Experimental Therapeutics Investigators' Consortium.<h2 class="st-heading-2">Lantern's Drug To Treat Soft Tissue Sarcomas</h2>Earlier this year, the FDA granted Orphan Drug Designation to Lantern Pharma's experimental drug LP-284 for the treatment of soft tissue sarcomas. It marked the third orphan designation for LP-284 and the sixth across the company’s pipeline.Orphan designation provides incentives to support the development of treatments for rare diseases affecting fewer than 200,000 people in the U.S.LP-284 is a small-molecule therapy designed to target cancer cells with DNA repair defects. The drug has shown encouraging activity in early studies, including a complete response in a heavily pretreated lymphoma patient in a Phase 1 trial.The therapy is currently being tested in patients with B-cell non-Hodgkin lymphomas.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/LTRN">LTRN</a> on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.<img src="https://news.stocktwits-cdn.com/LTRN_jpg_fb27c74f09.webp" alt="LTRN.jpg">The stock has been under heavy selling pressure, slumping more than 50% in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

LTRN Stock Gains 18% Pre-Market: FDA Greenlights First Pediatric Cancer Trial For Oncology Compound

The U.S. Food and Drug Administration cleared its Investigational New Drug application for Lantern Pharma’s oncology compound, paving the way for a Phase 1 clinical trial.

Why Did LTRN Stock Surge 18% In Pre-Market Today? 

Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001

Lantern Pharma Inc. (NASDAQ: LTRN) and its CNS-oncology focused wholly owned subsidiary Starlight Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared the...

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform...

$LTRN Q4 &#39;25 Earnings Results &amp; Recap

Lantern Pharma expects existing cash, cash equivalents, and marketable securities to fund operations until late July to mid-September 2026, requiring substantial additional funding in the near future.

Stocktwits

Lantern Pharma Inc

 Q4 '25 Earnings Results & Recap

Lantern Pharma expects existing cash, cash equivalents, and marketable securities to fund operations until late July to mid-September 2026, requiring substantial additional funding in the near future.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

Current Price	$1.42
Prev Close	$1.37
Open	$1.50
Dividend Yield	0.00%
50-Day Moving Average	$2.62
Beta	1.81
Avg. Volume	1.22M
PE Ratio	-0.90

52-Week High	$5.74
52-Week Low	$1.11
Market Capitalization	$15.42M
EPS (Annual)	-$1.57
Price to Book	2.45
Revenue Per Employee	$0.00

LTRN
Lantern Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LTRN News

LTRNLantern Pharma Inc